Heidelberg Pharma AG

Declaration of Voting Results & Voting Rights Announcements • Jun 10, 2010

News Details

Voting Rights Announcements | 10 June 2010 06:51

WILEX AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

WILEX AG / Release of an announcement according to Article 21, Section 1 of the WpHG [the German Securities Trading Act] (share)

10.06.2010 06:51

Dissemination of a Voting Rights announcement, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

WILEX AG: Publication according to Section 26 paragraph 1 of the Securities
Trading Act (Stimmrechtsmitteilung nach § 26 Abs. 1 Wertpapierhandelsgesetz
- WpHG) for Europe-wide distribution:

WILEX AG, Grillparzerstr. 10, 81675 Munich, Germany (WKN 661472, ISIN
DE0006614720 respectively) has received on 09 June 2010 the following
voting rights announcement pursuant to Section 21 para. 1 of the Securities
Trading Act [Wertpapierhandelsgesetz; WpHG]:

1. UCB Pharma S.A., Brussels, Belgium informed us on 09 June 2010
   according to Section 21 para. 1 of the Securities Trading Act, that
   their voting interest in WILEX AG has exceeded the threshold of 15% and
   amounted to 18.05% (2,880,069 voting rights) on 7 June 2010. Of these
   2,880,069 voting rights (18.05%), 1,818,181 voting rights (11.39%) and
   the underlying shares were directly held by UCB Pharma S.A. on 7 June
   1. The remaining 1,061,888 voting rights (6.65%) were attributed to
      UCB Pharma S.A. pursuant to Section 22 para. 1 sentence 1 no. 5 of the
      Securities Trading Act on such date.

From the following shareholder holding a voting interest of 3% or more in
WILEX AG voting rights were attributed to UCB Pharma S.A. on 7 June 2010:

• Apax Europe IV-A, L.P.

Furthermore UCB Pharma S.A. informed us voluntarily pursuant to Section 21
para. 1 of the Securities Trading Act, that on 9 June 2010 the voting
interest held by UCB Pharma S.A. in WILEX AG still exceeded the threshold
of 15% and amounted to 18.05% (2,880,069 voting rights). After the
completion of the acquisition of 1,061,888 shares (6.65%) in WILEX AG by
UCB Pharma S.A., all 2,880,069 voting rights (18.05%) and the underlying
shares were directly held by UCB Pharma S.A. on 9 June 2010.

1. UCB S.A., Brussels, Belgium, informed us on 09 June 2009 according to
   Section 21 para. 1 of the Securities Trading Act, that their voting
   interest in WILEX AG has exceeded the threshold of 15% and amounted to
   18.05% (2,880,069 voting rights) on 7 June 2010. Of these 2,880,069
   voting rights (18.05%), 1,818,181 voting rights (11.39%) were
   attributed to UCB S.A. pursuant to Section 22 para. 1 sentence 1 no. 1
   of the Securities Trading Act on 7 June 2010. The remaining 1,061,888
   voting rights (6.65%) were attributed to UCB S.A. pursuant to Section
   22 para. 1 sentence 1 no. 5 in conjunction with Section 22 para. 1
   sentence 2 of the Securities Trading Act on such date.

From the following company controlled by UCB S.A. and holding a voting
interest of 3% or more in WILEX AG voting rights were attributed to UCB
S.A. on 7 June 2010:

• UCB Pharma S.A.

From the following shareholder holding a voting interest of 3% or more in
WILEX AG voting rights were attributed to UCB S.A. on 7 June 2010:

• Apax Europe IV-A, L.P.

Furthermore, UCB S.A. informed us voluntarily pursuant to Section 21 para.
1 of the Securities Trading Act, that on 9 June 2010, the voting interest
held by UCB S.A. in WILEX AG still exceeded the threshold of 15% and
amounted to 18.05% (2,880,069 voting rights). After the completion of the
acquisition of 1,061,888 shares (6.65%) in WILEX AG by UCB Pharma S.A., a
company controlled by UCB S.A., all 2,880,069 voting rights (18.05%) were
attributed to UCB S.A. pursuant to Section 22 para. 1 sentence 1 no. 1 of
the Securities Trading Act on 9 June 2010.

From the following company controlled by UCB S.A. and holding a voting
interest of 3% or more in WILEX AG voting rights were attributed to UCB
S.A. on 9 June 2010:

• UCB Pharma S.A.

• Financière de Tubize S.A., Brussels, Belgium, informed us on 09 June
  2009 according to Section 21 para. 1 of the Securities Trading Act, that
  their voting interest in WILEX AG has exceeded the threshold of 15% and
  amounted to 18.05% (2,880,069 voting rights) on 7 June 2010. Of these
  2,880,069 voting rights (18.05%), 1,818,181 voting rights (11.39%) were
  attributed to Financière de Tubize S.A. pursuant to Section 22 para. 1
  sentence 1 no. 1 of the Securities Trading Act on 7 June 2010. The
  remaining 1,061,888 voting rights (6.65%) were attributed to Financière de
  Tubize S.A. pursuant to Section 22 para. 1 sentence 1 no. 5 in conjunction
  with Section 22 para. 1 sentence 2 of the Securities Trading Act.

From the following companies each controlled by Financière de Tubize S.A.
and each holding a voting interest of 3% or more in WILEX AG voting rights
were attributed to Financière de Tubize S.A. on 7 June 2010:

• UCB Pharma S.A.;

• UCB S.A.

From the following shareholder holding a voting interest of 3% or more in
WILEX AG voting rights were attributed to Financière de Tubize S.A. on 7
June 2010:

• Apax Europe IV-A, L.P.

Furthermore Financière de Tubize S.A. informed us voluntarily pursuant to
Section 21 para. 1 of the Securities Trading Act, that on 9 June 2010, the
voting interest held by Financière de Tubize S.A. in WILEX AG still
exceeded the threshold of 15% and amounted to 18.05% (2,880,069 voting
rights). After the completion of the acquisition of 1,061,888 shares
(6.65%) in WILEX AG by UCB Pharma S.A., a company controlled by Financière
de Tubize S.A., all 2,880,069 voting rights (18.05%) were attributed to
Financière de Tubize S.A. pursuant to Section 22 para. 1 sentence 1 no. 1
of the Securities Trading Act on 9 June 2010.

From the following companies each controlled by Financière de Tubize S.A.
and each holding a voting interest of 3% or more in WILEX AG voting rights
were attributed to Financière de Tubize S.A. on 9 June 2010:

• UCB Pharma S.A.;

• UCB S.A.

Munich, 10 June 2010

WILEX AG

Executive Management Board

10.06.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Internet: www.wilex.com

End of News DGAP News-Service

---